Search results for "breast neoplasm"

showing 10 items of 809 documents

Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1α

2007

We reported previously that the obesity hormone leptin is overexpressed in breast cancer biopsies. Here, we investigated molecular mechanisms involved in this process, focusing on conditions that are associated with obesity, that is, hyperinsulinemia and induction of hypoxia. By using quantitative real-time PCR, immunofluorescent detection of proteins and enzyme-linked immunosorbent assays, we found that treatment of MCF-7 breast cancer cells with high doses of insulin or the hypoxia-mimetic agent CoCl2, or culturing the cells under hypoxic conditions significantly increased the expression of leptin mRNA and protein. Notably, the greatest leptin mRNA and protein expression were observed und…

Transcriptional ActivationCancer Researchmedicine.medical_specialtyActive Transport Cell NucleusBreast NeoplasmsBiologymedicine.disease_causeleptinbreast cancerInternal medicineCoactivatorGene expressionTumor Cells CulturedGeneticsmedicineHumansInsulinHIFp300-CBP Transcription FactorsPromoter Regions GeneticMolecular BiologyCell NucleusRegulation of gene expressionBinding SitesLeptin receptorLeptinPromoterCobaltHypoxia-Inducible Factor 1 alpha SubunitCell HypoxiaGene Expression Regulation NeoplasticEndocrinologyhyperinsulinemiaCarcinogenesisChromatin immunoprecipitationhormones hormone substitutes and hormone antagonistsProtein BindingOncogene
researchProduct

Cadmium effects on p38/MAPK isoforms in MDA-MB231 breast cancer cells

2009

Emerging evidence seems to indicate that the heavy metal cadmium (Cd) is able to regulate gene expression, drastically affecting the pattern of transcriptional activity in normal and pathological eukaryotic cells, also affecting intracellular signalization events. Human p38 is a family of mitogen-activated protein kinases consisting of four isoforms (alpha, beta, gamma and delta) which mediate signal transduction cascades controlling several aspects of cell physiology. In this study we examined whether exposure of MDA-MB231 tumor cells from the human breast to Cd may exert some effect on p38 isoform expression and accumulation, as well as on p38 activation. Employing a combination of prolif…

Transcriptional ActivationGene isoformCadmium SB203580 p38 isoforms p38 activation Gene expressionCell SurvivalPyridinesp38 mitogen-activated protein kinasesBreast NeoplasmsBiologyp38 Mitogen-Activated Protein KinasesGene Expression Regulation EnzymologicGeneral Biochemistry Genetics and Molecular BiologyBiomaterialsStructure-Activity RelationshipGene expressionTumor Cells CulturedHumansSettore BIO/06 - Anatomia Comparata E CitologiaCell ProliferationRegulation of gene expressionDose-Response Relationship DrugKinaseImidazolesMetals and AlloysMolecular biologyCell biologyIsoenzymesCell cultureDrug Screening Assays AntitumorSignal transductionGeneral Agricultural and Biological SciencesIntracellularCadmiumBioMetals
researchProduct

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.

2010

The potent anti-tumour activities of gamma delta T cells have prompted the development of protocols in which gamma delta-agonists are administered to cancer patients. Encouraging results from small Phase I trials have fuelled efforts to characterize more clearly the application of this approach to unmet clinical needs such as metastatic carcinoma. To examine this approach in breast cancer, a Phase I trial was conducted in which zoledronate, a V gamma 9V delta 2 T cell agonist, plus low-dose interleukin (IL)-2 were administered to 10 therapeutically terminal, advanced metastatic breast cancer patients. Treatment was well tolerated and promoted the effector maturation of V gamma 9V delta 2 T …

Translational Studiesmedicine.medical_treatmentLymphocyte ActivationZoledronic AcidMetastasisTNF-Related Apoptosis-Inducing LigandProstate cancerT-Lymphocyte SubsetsImmunology and AllergyMedicineDiphosphonatesRemission InductionEsterasesImidazolesReceptors Antigen T-Cell gamma-deltaMiddle AgedMetastatic breast cancerTreatment Outcomemedicine.anatomical_structureDisease ProgressionCytokinesFemaleImmunotherapyBreast diseaseChemokinesT cellImmunologyBreast NeoplasmsInterferon-gammaHemiterpenesOrganophosphorus CompoundsBreast cancerAdjuvants ImmunologicVgamma9Vdelta2 T cells Zoledronate interleukin-2advanced breast cancer patientsHumansLymphocyte CountAgedCell ProliferationSalvage Therapybusiness.industryLysineMucin-1CancerImmunotherapymedicine.diseaseTumor Necrosis Factor Receptor Superfamily Member 7ImmunologyInterleukin-2Leukocyte Common Antigensbusiness
researchProduct

Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells.

2013

BACKGROUND: The Human Epidermal Growth Factor Receptor 2 (HER-2), overexpressed in 25-30% of breast carcinomas (BC), is the therapeutic target for trastuzumab, a recombinant humanized monoclonal antibody. The initial response to trastuzumab is often followed by drug-insensitivity within one year. Several hypotheses have been raised to explain this event, but the mechanisms behind the responses to trastuzumab are still unclear. Aim: To study the effects of short and prolonged trastuzumab treatment on the proteomic profiles of HER-2-overexpressing SKBR-3 BC cells. MATERIALS AND METHODS: Cells were treated with trastuzumab to obtain sensitive and resistant clones. The drug effects were evaluat…

Trastuzumab Herceptin(R) Breast Cancer ProteomicsBlotting WesternAntineoplastic AgentsBreast NeoplasmsTrastuzumabAntibodies Monoclonal HumanizedMass SpectrometrySettore BIO/13 - Biologia ApplicataDrug Resistance NeoplasmCell Line TumorHumansElectrophoresis Gel Two-DimensionalFemaleSettore BIO/06 - Anatomia Comparata E CitologiaTranscriptomeCell ProliferationAnticancer research
researchProduct

Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects

2022

Immunotherapy is improving the prognosis and survival of cancer patients, but despite encouraging out-comes in different cancers, the majority of tumors are resistant to it, and the immunotherapy combinations are often accompanied by severe side effects. Here, we show that a periodic fasting-mimicking diet (FMD) can act on the tumor microenvironment and increase the efficacy of immunotherapy (anti-PD-L1 and anti-OX40) against the poorly immunogenic triple-negative breast tumors (TNBCs) by expanding early exhausted effector T cells, switching the cancer metabolism from glycolytic to respiratory, and reducing collagen depo-sition. Furthermore, FMD reduces the occurrence of immune-related adve…

Tumor MicroenvironmentHumansTriple Negative Breast NeoplasmsFastingImmunotherapySettore MED/08 - Anatomia PatologicaGlycolysisnutrition triple-negative breast cancer CP: Cancer CP: Immunology fasting fasting-mimicking diet immunotherapy inflammationB7-H1 AntigenGeneral Biochemistry Genetics and Molecular BiologyCell Reports
researchProduct

Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility

2017

The importance of the immune system as a potent anti-tumor defense has been consolidated in recent times, and novel immune-related therapies are today demonstrating a strong clinical benefit in the setting of several solid neoplasms. Tumor-infiltrating lymphocytes reflect the attempt of the host to eradicate malignancies, and during the last decades, they have been shown to possess an interesting prognostic utility for breast cancer, especially in case of HER2 positive and triple-negative molecular subtypes. In parallel, the clinical evaluation of tumor-infiltrating lymphocytes has been shown to effectively predict treatment outcomes in both neoadjuvant and adjuvant settings. Currently, tu…

Tumor-infiltrating lymphocytes; breast cancer; cancer immunotherapy0301 basic medicineOncologyCA15-3medicine.medical_specialtymedicine.medical_treatmentCA 15-3Tumor-infiltrating lymphocyteBreast NeoplasmsTumor-infiltrating lymphocytes03 medical and health sciencesLymphocytes Tumor-Infiltratingbreast cancer0302 clinical medicineImmune systemBreast cancerCancer immunotherapyInternal medicinemedicineHumansRC254-282cancer immunotherapyTumor-infiltrating lymphocytesbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerGeneral MedicinePrognosismedicine.diseaseNeoadjuvant TherapyTreatment Outcome030104 developmental biologyImmunoediting030220 oncology & carcinogenesisFemalebusinessTumor Biology
researchProduct

Olive oil intake and cancer risk: A systematic review and meta-analysis

2022

Background Research evidence has established the beneficial effects of diet in cancer prevention; various epidemiological studies have suggested that olive oil component could play a role in decreasing cancer risk. This systematic review and meta-analysis aims to investigate the association between olive oil consumption, cancer risk and prognosis. Methods A systematic search was conducted in PubMed, EMBASE and Google Scholar databases (end-of-search: May 10, 2020). Pooled relative risk (RR) and 95% confidence intervals (95% CIs) were estimated with random-effects (DerSimonian-Laird) models. Subgroup analyses, sensitivity analyses and meta-regression analysis were also performed. Results 45…

Urologic NeoplasmsDatabases FactualEpidemiologyScienceUrologyBreast NeoplasmsGastroenterology and HepatologyResearch and Analysis MethodsVegetable OilsFruitsMathematical and Statistical TechniquesRisk FactorsPlant ProductsNeoplasmsBreast TumorsBreast CancerGastrointestinal CancersMedicine and Health SciencesHumansStatistical MethodsOlive OilGastrointestinal NeoplasmsColorectal CancerMultidisciplinaryCancer Risk FactorsProstate CancerQStatisticsROrganismsProstate DiseasesBiology and Life SciencesCancers and NeoplasmsEukaryotaOlivesAgriculturePlantsMetaanalysisAgronomyGenitourinary Tract TumorsOncologyMedical Risk FactorsCase-Control StudiesPhysical SciencesMedicineFemaleMathematicsResearch ArticleCrop SciencePLOS ONE
researchProduct

Dietary exposure in utero and during lactation to a mixture of genistein and an anti-androgen fungicide in a rat mammary carcinogenesis model

2015

Endocrine disruptors may play substantial roles in the high incidence of breast cancer. We previously described how early exposure to the mixture of phytoestrogen genistein (G) and the anti-androgen vinclozolin (V) affects peripubertal mammary development. This study evaluates the carcinogenic potential of exposure to V alone or associated with G from conception until weaning in Wistar rats. Dams were exposed to V, G or GV during pregnancy/lactation. At PND50 offspring were treated with DMBA[7,12-dimethylbenz(a)anthracene]. V or GV maternal exposure decreased number of DMBA-induced mammary tumors in the offspring, without significant modifications in tumor incidence, multiplicity and latenc…

[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionGenisteinDMBAEndocrine DisruptorsToxicologymedicine.disease_causechemistry.chemical_compound0302 clinical medicinePregnancyRisk FactorsLactationVinclozolinOxazoles0303 health sciencesAge Factorsendocrine disruptionGenisteinTumor Burden3. Good health[ SDV.BDLR ] Life Sciences [q-bio]/Reproductive Biologymedicine.anatomical_structuregestational and lactational exposureReceptors EstrogenMaternal ExposureIn utero030220 oncology & carcinogenesisphytoestrogenFemaleReceptors ProgesteroneCarcinoma in Situmedicine.medical_specialtyendocrine systemanti-androgenOffspring910-Dimethyl-12-benzanthraceneBreast NeoplasmsGestational AgeBiologyRisk Assessment03 medical and health sciencesMammary Glands AnimalPrenatal Educationmammary gland carcinogenesisInternal medicinemedicineAnimalsEndocrine systemRats WistarCell Proliferation030304 developmental biologyAndrogen AntagonistsEpithelial Cells[SDV.BDLR]Life Sciences [q-bio]/Reproductive BiologyDietFungicides IndustrialDisease Models AnimalEndocrinologychemistryCarcinogenesis[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Proton-irradiated breast cells: molecular points of view

2019

Abstract Breast cancer (BC) is the most common cancer in women, highly heterogeneous at both the clinical and molecular level. Radiation therapy (RT) represents an efficient modality to treat localized tumor in BC care, although the choice of a unique treatment plan for all BC patients, including RT, may not be the best option. Technological advances in RT are evolving with the use of charged particle beams (i.e. protons) which, due to a more localized delivery of the radiation dose, reduce the dose administered to the heart compared with conventional RT. However, few data regarding proton-induced molecular changes are currently available. The aim of this study was to investigate and descri…

breast cancer cDNA microarray gene signature proton therapy radiation Breast Breast Neoplasms Cell Line Tumor DNA Complementary Dose-Response Relationship Radiation Female Gene Expression Profiling Gene Expression Regulation Neoplastic Humans Inflammation MCF-7 Cells Oligonucleotide Array Sequence Analysis Phenotype Proton Therapy Radiation Tolerance Radiotherapy ProtonsDNA ComplementaryHealth Toxicology and Mutagenesismedicine.medical_treatmentBreast NeoplasmsCell fate determinationRadiation Tolerancegene signature03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerCell Line TumorRegular Papermedicineproton therapyHumansRadiology Nuclear Medicine and imagingBreastClonogenic assayBiologyProton therapyOligonucleotide Array Sequence Analysis030304 developmental biologyInflammationcDNA microarray0303 health sciencesRadiotherapyChemistryGene Expression ProfilingBreast cancer; radiation; cDNA microarray; gene signature; proton therapyCancerDose-Response Relationship RadiationGene signaturemedicine.diseaseGene Expression Regulation NeoplasticGene expression profilingRadiation therapyradiationPhenotype030220 oncology & carcinogenesisMCF-7 CellsCancer researchFemaleProtons
researchProduct

High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast can…

2021

Oestrogen receptor (ER)-negative (–) progesterone receptor (PgR)-positive (+) is the least common combination of steroid receptor expression observed in breast cancer. There are many controversies regarding the actual existence of ER–/PgR+ phenotype. In the current study, we aimed to perform comprehensive immunohistochemical re-evaluation of ER–/PgR+ breast cancers from multiple institutions. A total of 135 cases of ER–/PgR+ breast cancer were collected from 11 institutions from the period 2006–2020 and subsequently stained with three clinically validated anti-ER antibody clones: SP1 (Roche), 1D5 (Dako), and EP1 (Dako), and two anti-PgR antibody clones: 636 (Dako), and 1E2 (Roche). Clinicop…

breast cancerReceptors EstrogenOestrogen receptorReceptor ErbB-2immunohistochemistryHumansBreast NeoplasmsFemaleprognosisReceptors Progesteroneprogesterone receptorPathology and Forensic MedicinePathology
researchProduct